Compare BCG & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCG | LGVN |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.4M | 25.9M |
| IPO Year | 2025 | 2021 |
| Metric | BCG | LGVN |
|---|---|---|
| Price | $1.56 | $0.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 45.6K | ★ 328.1K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 112.50 | 50.76 |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $187,144,000.00 | $709,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.81 |
| P/E Ratio | $17.22 | ★ N/A |
| Revenue Growth | ★ 10.80 | N/A |
| 52 Week Low | $1.26 | $0.48 |
| 52 Week High | $3.44 | $1.23 |
| Indicator | BCG | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 57.94 | 56.26 |
| Support Level | $1.43 | $0.61 |
| Resistance Level | $1.61 | $0.87 |
| Average True Range (ATR) | 0.10 | 0.06 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 75.00 | 75.46 |
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.